相关实验视频

Updated: May 11, 2025

A 3D Organotypic Melanoma Spheroid Skin Model

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

蛋白激酶C抑制克服了皮肤黑色素瘤的向治疗阻力

Corinne I Stoffel¹, Ossia Eichhoff¹, Phil F Cheng¹

¹Department of Dermatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.

Experimental dermatology

|April 17, 2025

概括

向蛋白激酶C (PKC) 和基激活蛋白激酶 (MAPK) 途径可以克服黑色素瘤中的抗性. 结合PKC和MAPK抑制剂可减少瘤生长和侵袭,提供一种新的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
皮肤病学皮肤病学

背景情况:

WNT5a的表达与黑色素瘤中MAPK抑制剂耐药性相关,促进细胞极性和入侵.
目前还没有针对WNT5a的特定小分子.
之前的研究表明,泛蛋白激酶C (PKC) 抑制剂在准WNT5a依赖的WNT信号传递中取得了成功.

研究的目的:

调查皮肤黑色素瘤中PKC抑制的相关性.
探索结合PKC和基因激活蛋白激酶 (MAPK) 途径抑制的潜力,以治疗耐治疗黑色素瘤.

主要方法:

研究了皮肤黑色素瘤中PKC信号与WNT5a表达之间的关联.
评估了单独使用泛 PKC 抑制剂以及与 MAPK 途径抑制剂,体外和体外异种移植模型的疗效.
评估了扩散,入侵和亡诱导作为关键结果措施.

主要成果:

确定了PKC信号与WNT5a表达之间的积极反循环,这表明泛PKC抑制剂可以在皮肤黑色素瘤中准WNT5a.
结合PKC和MAPK通路的抑制通过诱导亡,显著降低了黑色素瘤细胞的增殖和侵入在体外.
在体内异种移植研究显示,与标准护理相比,单一和组合PKC抑制剂治疗减少了增殖和增加了亡.

结论:

通过联合PKC和MAPK抑制准非正规的WNT信号通路是治疗耐药性皮肤黑色素瘤的一个有前途的策略.
这种组合方法在体内有效打击瘤异质性.
该研究提出这种策略作为未来皮肤黑色素瘤临床干预的潜在替代方案.

关键词:

在 PKC PKC 里面,在WNT信号中使用WNT信号.这是皮肤黑色素瘤.现象型切换转换现象型切换电阻的阻力可以这就是Sotrastaurin.

更多相关视频

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

A Melanoma Patient-Derived Xenograft Model

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Mitogens and the Cell Cycle

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...